血小板增多与肝细胞癌。
Thrombocytosis and hepatocellular carcinoma.
机构信息
Department of Nutritional Carcinogenesis, IRCCS S. de Bellis, National Institute for Digestive Diseases, Via Turi 27, 70013, Castellana Grotte, BA, Italy.
出版信息
Dig Dis Sci. 2013 Jun;58(6):1790-6. doi: 10.1007/s10620-012-2527-3. Epub 2013 Jan 12.
BACKGROUND
Thrombocytopenia has been reported to be both a risk factor for hepatocellular carcinoma (HCC) development as well as a prognostic factor. Many HCCs also occur in presence of normal platelets.
AIM
To examine a cohort of HCC patients with associated thrombocytosis.
METHODS
Records were examined of a cohort of 634 biopsy-proven and randomly presenting HCC patients without thrombocytopenia.
RESULTS
In the total cohort, 52 patients were identified with thrombocytosis (platelet levels >400 × 10(9)/L) and compared with 582 patients with normal platelet values. The average tumor sizes were 13.1 versus 8.8 cm (p < 0.0001), and their total average bilirubin levels were 0.9 versus 1.5 (p = 0.02), comparing thrombocytosis patients versus normal platelet count HCC patients. These differences were even more pronounced in patients with HCC sizes >5 cm. Thrombocytosis patients were younger and had less cirrhosis, but similar percent with hepatitis B or C or alcohol consumption.
CONCLUSION
Thrombocytosis in association with HCC occurs in patients with larger tumor sizes and better liver function.
背景
血小板减少既被认为是肝细胞癌（HCC）发展的危险因素，也是预后因素。许多 HCC 也发生在血小板正常的情况下。
目的
检查一组伴有血小板增多的 HCC 患者。
方法
检查了 634 名经活检证实且随机出现 HCC 患者的队列记录，这些患者没有血小板减少症。
结果
在总队列中，有 52 名患者被确定为血小板增多症（血小板水平>400×10(9)/L），与 582 名血小板正常的患者进行比较。平均肿瘤大小分别为 13.1 厘米与 8.8 厘米（p<0.0001），总胆红素水平分别为 0.9 与 1.5（p=0.02），血小板增多症患者与血小板计数正常的 HCC 患者相比。在肿瘤大小>5 厘米的患者中，这些差异更为明显。血小板增多症患者更年轻，肝硬化程度较低，但乙型肝炎或丙型肝炎或饮酒的百分比相似。
结论
与 HCC 相关的血小板增多症发生在肿瘤较大且肝功能较好的患者中。
Zotero 插件